|
LVT News Releases Hello Everyone! We are pleased to bring to your attention a recent IPO in the psychedelics, health and wellness space: Levitee Labs inc. (LVT.CSE) We recently had the privilege of speaking with Levitee Labs CEO: Pouya Farmand and were instantly drawn to their “Roll Up” model. In a sector currently worth over $100 Billion and climbing, Levitee labs is continually looking for opportunities to increase their footprint in the psychedelics space. Levitee Labs possesses intellectual property in Monke Neutraceuticals and Sporeo Supply. It is projected that these two divisions alone will generate approximately 23% of the company’s total revenue with 77% being produced through their most recent and future acquisitions going forward. As of July 21st 2021, the company issued a news release confirming the acquisition of five addictions clinics and three specialized pharmacies in Alberta, Canada. All eight facilities specialize in addictions treatment as well as pain and mental health management. In addition, all clinics and pharmacies are “turn-key” in nature resulting in immediate positive cashflow for the company starting at $1 million per year. (please see due diligence below). We were impressed at the rate with which Mr. Farmand and his team were able to expand and generate positive cashflow since their recent Initial Public Offering and listing on the CSE. As mentioned above, within a week of lisiting, Levitee labs issued a flurry of news releases outlining multiple acquisitions. It is our understanding that the company plans on reaching an eventual acquisition target of over $500 million in assets. To compliment their expansion, Levitee Labs is committed to making strategic acquisitions which can further bolster the efficiency and sales of their existing portfolio. In this way, the company looks to position itself to be a “one-stop-shop” conglomerate by: Providing necessities for small to large scale cultivation of psychedelics, Creating psychedelic based health and wellness products; and, Offering alternative treatment from Medical clinics and pharmacies in order to alleviate pain, manage addictions and mental health.
With this most recent expansion, Levitee labs is poised to become the first EBITDA-positive psychedelics company with a projected 2021 revenue of $15.4m from all assets/revenue streams. We recently took a position at 52 cents and will continue to add as this story unfolds. The company’s nearest competitors (see below) have an average market capitalization of ~$378 million. It is our opinion that Levitee Labs is poised to grow 7-10x from its current market value in due course. In closing, we noted a well laid out share structure. With approximately 96% of all outstanding shares possessing selling restrictions at the time of writing and ~53% insider ownership, we see a solid base going forward stabilizing the share price. As always, seek professional financial advice and conduct your own due diligence prior to making any investment decisions, Paradigm Market Research inc. See our overview below for additional details. Consider supporting our free newsletter at: https://www.paradigmresearch.ca/our-team Check out www.paradigmresearch.ca to view more of our content.
|
